8-K: Damora Therapeutics CFO Departs, New Finance Chief Appointed

Damora Therapeutics announced the departure of its CFO, Lori Firmani, effective May 1, 2026, with Brian Burkavage appointed as the new principal financial and accounting officer.

Summary

• Lori Firmani will cease serving as Chief Financial Officer of Damora Therapeutics, Inc. effective May 1, 2026.
• Ms. Firmani will receive separation benefits in accordance with the Company's Executive Separation Benefits Plan, including base salary continuation, pro-rated target bonus, a health savings account contribution of $6,000, and full acceleration of outstanding equity awards, subject to signing a separation agreement.
• Brian Burkavage, currently Senior Vice President, Finance, has been appointed as the Company's principal financial officer and principal accounting officer, effective May 1, 2026.
• Mr. Burkavage has extensive experience, including previous roles at IO Biotech, Inc., Passage Bio, Inc., Aclaris Therapeutics, Inc., and Ernst & Young LLP.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while a CFO departure can introduce uncertainty, the immediate appointment of an experienced successor mitigates significant negative impact.

Positives

• Smooth transition of financial leadership with the immediate appointment of a successor.
• Ms. Firmani's separation package includes full acceleration of equity awards, potentially benefiting her.
• Mr. Burkavage brings a strong financial background with over a decade at Ernst & Young and experience in biotech finance.

Negatives

• Departure of the Chief Financial Officer, Lori Firmani, effective May 1, 2026.
• The reason for Ms. Firmani's departure is not explicitly stated beyond her ceasing to serve in the role.

Risks

• Potential disruption to financial operations during the leadership transition, although mitigated by immediate appointment of successor.
• Uncertainty regarding the long-term financial strategy with a change in CFO.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing regarding future financial performance or strategic direction.

Management Comments

• The Board of Directors determined that Lori Firmani would cease serving as the Company's Chief Financial Officer.
• Brian Burkavage was appointed as the Company's principal financial officer and principal accounting officer.

Industry Context

StockSavvy.ai notes that executive turnover, particularly in finance roles, is not uncommon in the dynamic biotechnology sector, especially following significant events like acquisitions. The swift appointment of a successor with relevant experience suggests a focus on maintaining financial stability.

Management Changes

Stakeholder Impact

• Shareholders: Potential short-term uncertainty regarding financial leadership, but mitigated by the appointment of an experienced successor.
• Employees: May experience some uncertainty regarding financial strategy and operations during the transition.
• Creditors: No immediate impact indicated, as financial leadership remains in place with an experienced individual.

Next Steps

• Lori Firmani to execute and not revoke a separation agreement and general release of claims.
• Brian Burkavage to enter into the Company's standard form of indemnification agreement for executive officers.

Key Dates

Keywords

CFO Departure, Financial Officer Appointment, Damora Therapeutics, SEC Filing, Form 8-K, Corporate Governance, Executive Changes, Biotechnology